Home > Reports > Nifedipine Market: Information by Type (Nifedipine Controlled-Release Tablets), Application (Heart Failure), Distributio

Nifedipine Market: Information by Type (Nifedipine Controlled-Release Tablets), Application (Heart Failure), Distribution Channel (Hospital Pharmacies), and Region — Forecast till 2029

Market Snapshot
Study Period:
2017-2029
Base Year:
2021
Fastest Growing Market:
Europe
Largest Market:
North America
CAGR:
8.49 %
Key Players
GlaxoSmithKline plc

Novartis AG

Merck & Co Inc

Abbott Laboratories

Boehringer Ingelheim GmbH

Nifedipine is a calcium channel blocker that prevents calcium from moving through the arteries walls. Nifedipine is used to treat high blood pressure, arrhythmias, and angina. It also has other therapeutic uses, including ryanoids syndrome, cephalalgia, etc.

The market is fueled by an increase in the senior population, healthcare expenditure, the incidence of chronic conditions such as heart failure, arrhythmias, hypertension, and healthcare awareness. However, government controls and adverse pharmacological effects such as hypotension, stomach ulcers, and congestive heart failure limit the market growth. New development prospects are expected to emerge from ongoing R&D operations. 

The global nifedipine market was valued at USD 856.66 million in 2020 and is expected to reach a market valuation of USD 1,792.36 million by 2029, accounting for 8.49% CAGR during the forecast period.

The study of the scope of the global nifedipine market includes the market size analysis of the manufacturer's products and strategies.

A Rise in the Geriatric Population and Chronic Heart Diseases to Amplify the Nifedipine Market

Globally, the number of elderly is increasing faster due to high life expectancy and falling fertility levels. As per United Nations, people aged 65 or above have outnumbered children under five years of age worldwide. According to the WHO, the global population aged 60 years and above is expected to rise to a total of 2 billion by 2050, up from 900 million in 2015.

Table: Number of persons aged 65 years or over by geographic region in 2019

Regions

Number of People Aged 65 or over in 2019 (Millions)

Sub-Saharan Africa

31.9

Northern Africa and Western Asia

29.4

Central and Southern Asia

119.0

Eastern and South-Eastern Asia

260.6

Latin America and the Caribbean

56.4

Australia and New Zealand

4.8

Oceania, excluding Australia and New Zealand

0.5

Europe and Northern America

200.4

Source: United Nations, Department of Economic and Social Affairs, Population Division (2019). World Population Prospects 2019

The above table depicts that the population base of people belonging to the 65 years older category is growing, which are at higher risk of heart and vascular conditions. For instance, as per HealthinAging.org, in people over the age of 65, heart failure is the main cause of hospitalization. It also added that the lifetime risk of suffering heart failure in both men and women at 80 is 20%. 

Conclusively, the rise in the geriatric population and the growing prevalence of chronic heart diseases are anticipated to boost the market growth globally. 

Side Effects of Nifedipine Medication to Impede the Market Growth

The common side effects associated with nifedipine are a matter of concern. Swelling of extremities, dizziness, flushing, headache, heartburn, nausea, muscle cramps, mood change, nervousness, cough, hives, itching, constipation, among others, are frequently observed side effects while using nifedipine. 

Moreover, post-marketing side effects of nifedipine reported include:

  • Exfoliative or bullous skin adverse events (e.g., erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis)
  • Photosensitivity reactions
  • Acute generalized exanthematous pustulosis

Such safety and tolerability concerns with the use of nifedipine medication are expected to impede the market growth during the forecast period. 

Growing Demand for Nifedipine in Developing Countries to Attract the Market Growth Opportunities

Factors such as rise in incidence and prevalence of target diseases, including cardiovascular conditions, preterm labor and Raynaud's syndrome, large patient population, increasing healthcare infrastructure mainly in Asian countries is anticipated to propel the market growth in emerging economies of the Asia-Pacific region such as China, India, and South Korea. In 2016, as per a study reported by AHA journals, the prevalence of CVDs was estimated to be 54.5 million in India.

In addition, favorable government support would lead to market expansion. For instance, in 2017, the National Health Policy of India intended to reduce 25% of premature deaths from cardiovascular diseases through screening and treatment of more than 80% of hypertensive patients by the year-end of 2025. Furthermore, the Rashtriya Arogya Nidhi (RAN) scheme offers financial assistance to below poverty line patients; such initiatives further boost demand for the market.

Also, GlaxoSmithKline Plc (GSK), a major player in the market, has opted to invest USD 1 billion in its Indian pharmaceutical subsidiary, betting on increased demand in emerging markets as sales in established markets stagnate due to a wave of patent expirations. With the current India agreement, GSK plans to invest about USD 2 billion in two publicly traded Indian companies over the next year, the company's largest incremental investment in any country during that time.

Thus, growing efforts by key market players and a rising geriatric population base that is at high risk for acquiring target diseases in developing economies will create significant demand in the coming future. 

Impact of COVID-19 and its Challenges

The fundamental challenge during COVID-19 was that health care systems around the world could not cope with any medical disorders other than COVID-19 treatment, leading to a shift from patient-centered medicine towards a community-centered approach. 

Existing clinical guidelines mandate COVID-19 swabbing/testing to avoid unprotected contact with positive or suspicious COVID-19 patients to protect the hospital staff from infection for their personal and patients' safety. 

These mandates have imposed a home quarantine restriction and dramatically reduced working for medical staff. This crisis has ultimately altered everyday healthcare practice, negatively impacting patient outcomes. 

Segmental Analysis of the Nifedipine Market

Based on type, the segment is divided into nifedipine controlled-release tablets and nifedipine extended action tablets. In 2021, nifedipine controlled-release tablets captured the highest market share. This major share is attributed to the rise in incidences of hypertension and heart failure, use of ground-breaking technology for the development of medicines, growth in funding from the government and international organizations, and growing awareness regarding preventive care.

Based on application, the segment is divided into primary pulmonary hypertension, heart failure, Raynaud's syndrome, cephalalgia, and others. Primary pulmonary hypertension ranked highest in 2021. This is owing to obesity, poor dietary habits, excessive junk food consumption, a lack of exercise, a rising tendency of smoking and alcohol consumption among the younger generation, and stress. The growing government and private organizations initiatives and company programs for the development of advanced medications to treat hypertension and diabetes are anticipated to drive this segment.

By distribution channel, the global nifedipine market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held a dominating share of the global market in 2020 and is likely to grow at a higher CAGR during the forecast period.

Regional Analysis of the Nifedipine Market

The Supremacy of American Market Over Others

The North American nifedipine market has the highest revenue share and is expected to grow over the forecast period. The growth is expected due to the rise in chronic long-term illnesses as a dangerous health threat worldwide. Moreover, the trend of using calcium channel blocking drugs such as Nicardipine, Norvasc, Procardia, among others, have increased post-COVID-19 with an escalation in acute and chronic health abnormalities in the region. 

Also, obesity affects roughly 332,915,000 adults or 36.20% in the United States. People's poor lifestyles bring them closer to ailments like high blood pressure, chest aches, heart attacks, etc. As a result, the overall rate of drug consumption is increasing, driving up demand for Nifedipine. In terms of obesity rates, the United States surpassed every other country in 2021. Around 36.20% of adults in the United States are overweight, making calcium channel blocker medications the most popular.

Competitive Landscape

The worldwide market's competitiveness among big companies is moderate. However, as the market becomes saturated with increased participation from new entrants, we expect competitiveness to improve by margins.

Major Players Involved in the Market are

  • GlaxoSmithKline plc
  • Novartis AG
  • Merck & Co., Inc.
  • Abbott Laboratories
  • Boehringer Ingelheim GmbH
  • AstraZeneca plc
  • Hoffmann-La Roche AG
  • Teva Pharmaceutical Industries Ltd.
  • Vectura Group plc
  • Pfizer Inc.
  • Others

Key Developments:

  • On April 23, 2021, a German nifedipine manufacturer, MNC, declared that the supply of 30mg Adalat LA prolonged-release tablets to the United Kingdom had been restarted. Due to a shortage, the tablets mentioned above were out of stock in the UK earlier this year. Alliance healthcare difficulties were the root of the manufacturing problems, which have been resolved for the time being. Furthermore, prolonged-release tablets have proven the most efficient treatment among the many nifedipine medications.

Global Nifedipine Market: Segmentation

By Type

  • Nifedipine Controlled-Release Tablets
  • Nifedipine Extended Action Tablets

By Application

  • Primary Pulmonary Hypertension
  • Heart Failure
  • Raynaud’s Syndrome
  • Cephalalgia
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

By Regions 

  • Americas
  • Europe
  • Asia-Pacific
  • The Middle East and Africa

Frequently Asked Questions (FAQs)

Hospital Pharmacies Segment is expected to be the leading segment in Nifedipine Market during the forecast period.
The global nifedipine market was valued at USD 856.66 million in 2020 and is expected to reach a market valuation of USD 1,792.36 million by 2029, accounting for 8.49% CAGR during the forecast period.
GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Abbott Laboratories, Boehringer Ingelheim GmbH, AstraZeneca plc, Hoffmann-La Roche AG are the top players in Nifedipine Market.
North America is expected to hold the highest market share in Nifedipine Market.
The rise in the geriatric population and the growing prevalence of chronic heart diseases are the key factors expected to drive Nifedipine Market during the forecast period.
The global Nifedipine Market will be estimated to grow from the years 2017-2029.
In 2029 Global Nifedipine Market was valued at USD 1,792.36 million.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically, choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.
Table of Content Download Sample

Copyright . All rights Reserved By Straits Research